ArticleSmart molecules : open access2026
Photostabilized halocyanine for near-infrared excited bimodal photothermal synergism and tumor-targeted therapy.
Article in Smart molecules : open access, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work, we replaced hydrogen with halogen atoms in the BC7 molecule to enhance the parent molecule's photostability and improve the photothermal therapy (PTT) and photodynamic therapy (PDT) effects. We further improve and enhance the properties of BC7 while maintaining its optical properties, tumor targeting, and optical therapeutic effects. Nuclear magnetic resonance (NMR) spectroscopy of the four synthesized compounds confirms the success of the target products. We briefly screen BC7-Cl, BC7-Br, and BC7-I by in vitro photothermal experiments, in-solution reactive oxygen species detection, and stability tests. We intravenously inject three molecules into a tumor-bearing mouse model for in vivo tumor imaging and observe that their tumor-targeting ability has been markedly improved. In further optical treatment experiments, BC7-Br showed the best therapeutic effect and a significant improvement compared to BC7. This study provides innovative strategies and theoretical support for the construction and development of new materials with dual functions of efficient PTT and PDT.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.